INTRODUCTIONHuman papillomavirus (HPV) is an established risk factor for invasive cervical cancer (ICC). It is well known that various HPV types infect the genital tract of many healthy young women, and persistent infection with certain HPV types deemed high risk induce cervical cancer. International prevalence studies have estimated that approximately 70% of ICCs are positive for HPV‐16 and ‐18, and approximately 27% of ICC involve the remaining high‐risk types or other types. HPV tests identifying HPV‐16 and ‐18 are valuable in screening for cervical cancer since those cases are at higher risk of malignant progression.There are at least 193 distinct molecular tests that are commercially available in the global market for the detection of HPV in cervical specimens. In studies using these HPV tests, a meta‐analysis showed that approximately 10% of cervical cancers tested negative for HPV. In many large‐scale epidemiological studies, PCR assays using the HPV L1 gene consensus primer sets, such as GP5+/GP6+, MY09/MY11, SPF‐10, and L1C1/L1C2 + L1C2M have been used. The advantage of these approaches is amplifying the L1 gene region for various HPV types in one reaction tube. However, these approaches have the disadvantage of lower sensitivity in unique HPV types with many mismatch sequences between
Journal of Medical Virology – Wiley
Published: Jan 1, 2018
Keywords: ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud